Annovis Bio (NYSE:ANVS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Annovis Bio (NYSE:ANVS) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

A number of other analysts have also weighed in on the stock. Rodman & Renshaw reaffirmed a buy rating and issued a $67.00 price target on shares of Annovis Bio in a research note on Tuesday, July 2nd. EF Hutton Acquisition Co. I upgraded shares of Annovis Bio to a strong-buy rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Annovis Bio currently has a consensus rating of Buy and an average price target of $33.60.

Annovis Bio Trading Up 5.1 %

Shares of NYSE:ANVS opened at $8.43 on Tuesday. The company has a 50 day moving average of $8.57 and a 200-day moving average of $8.86. The firm has a market cap of $94.17 million, a P/E ratio of -1.47 and a beta of 1.72. Annovis Bio has a twelve month low of $4.53 and a twelve month high of $22.49.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. Equities research analysts forecast that Annovis Bio will post -2.53 EPS for the current year.

Institutional Trading of Annovis Bio

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Annovis Bio by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock worth $4,260,000 after purchasing an additional 20,588 shares during the period. Redmond Asset Management LLC boosted its stake in Annovis Bio by 6.1% in the 1st quarter. Redmond Asset Management LLC now owns 36,157 shares of the company’s stock worth $430,000 after purchasing an additional 2,077 shares during the period. XTX Topco Ltd acquired a new position in Annovis Bio in the 2nd quarter worth approximately $115,000. Greenwich Wealth Management LLC boosted its stake in Annovis Bio by 19.9% in the 2nd quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the period. Finally, Cetera Advisors LLC acquired a new position in Annovis Bio in the 1st quarter worth approximately $122,000. 15.83% of the stock is currently owned by institutional investors.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.